In Brief: FDA's Division of General and Restorative Devices
This article was originally published in The Gray Sheet
Executive Summary
FDA's Division of General and Restorative Devices: Office of Device Evaluation division assumes responsibility for all neurological device premarket reviews effective Oct. 1. Formerly reviewed by ODE's Division of Cardiovascular, Respiratory and Neurological Devices, responsibility for the products was transferred to DGRD to prevent any overlap of efforts resulting from the restorative nature of the neurological products, FDAers say. Two DCRND reviewers have moved to DGRD, which will spread the added workload among the four existing branches as appropriate...
You may also be interested in...
Respiratory Device Hand-off To FDA Dental Group Intended To Achieve Parity
Responsibility for reviewing respiratory device-related premarket submissions is expected to be transferred out of FDA's Division of Cardiovascular and Respiratory Devices (DCRD) to the Division of Dental, Infection Control and General Hospital Use Devices (DDIGD).
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.